NCT04342793View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

May 11, 2021

Study Completion Date

May 11, 2021

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

Placebo oral tablet

Placebo

DRUG

ALS-L1023 1,200mg

ALS-L1023

DRUG

ALS-L1023 1,800mg

ALS-L1023

Trial Locations (1)

04763

Hanyang University Seoul Hospital, Seoul

All Listed Sponsors
lead

AngioLab, Inc.

INDUSTRY

NCT04342793 - A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH | Biotech Hunter | Biotech Hunter